We read with interest the article by Li and colleagues1 on dexmedetomidine administration for brain tumour resection and postoperative delirium. The primary hypothesis of this randomised trial is that intraoperative dexmedetomidine administration reduces postoperative delirium at 5 days. We believe that some aspects are worthy of further discussion
Akça, B., Salaj, C.s., Bilotta, F. (2023). Dexmedetomidine administration during brain tumour resection and postoperative delirium: a randomised controlled trial. Comment on Br J Anaesth 2023; 130: e307-e316. BRITISH JOURNAL OF ANAESTHESIA, 1-2 [10.1016/j.bja.2023.04.012].
Dexmedetomidine administration during brain tumour resection and postoperative delirium: a randomised controlled trial. Comment on Br J Anaesth 2023; 130: e307-e316
Bilotta, F
2023-01-01
Abstract
We read with interest the article by Li and colleagues1 on dexmedetomidine administration for brain tumour resection and postoperative delirium. The primary hypothesis of this randomised trial is that intraoperative dexmedetomidine administration reduces postoperative delirium at 5 days. We believe that some aspects are worthy of further discussion| File | Dimensione | Formato | |
|---|---|---|---|
|
2023 1-s2.0-S0007091223001885-main.pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
83.29 kB
Formato
Adobe PDF
|
83.29 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
